Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

This page is alzhub.org's plain-English summary of a published study, not the paper itself. It is generated from the record we hold for this study, sourced and linked below — check the original for the full text and methods.

✓ Peer-reviewed alzhub usefulness score 47 out of 100. Disparities

Topic: Risk, prevention and care in population studies

Objective To evaluate the clinical presentations and dominant symptoms of patients with postmortem proven cortical-basal ganglionic degeneration (CBGD) from one neuropathology center. Background CBGD is a rare but increasingly recognized condition with clinical and pathologic features that continue to evolve. Attempts have been made to develop clinical criteria to enhance the specificity of diagnosis, but it is not clear what proportion of patients harboring CBGD disease present in the "classical" fashion versus other presentations. Previous large-case series that emphasize a parietal/perceptual-motor presentation may be biased because the cases mainly originate from movement disorder centers. Methods Thirteen cases of pathologically confirmed CBGD with sufficient clinical data were identified from a single neuropathology center between 1981 and 1996. Results Before death, only 4 of the 13 patients had a clinical diagnosis of CBGD, 6 had a clinical diagnosis of Alzheimer's disease (AD), 1 had AD and parkinsonism, and 2 had an atypical dementia of the frontotemporal type. Nine of 13 cases had early dementia. Conclusions Dementia was the most common presentation of CBGD in this study. Despite the best efforts to define criteria to enhance the specificity of a diagnosis of CBGD, it is becoming clear that the clinical syndrome that accompanies this disease is quite varied. Unfortunately, patients fulfilling classical diagnostic criteria may represent a minority of those with this pathologic diagnosis.

Cite this study APA, Vancouver, BibTeX · download .bib or .ris

APA 7th

Grimes, D. A., Lang, A. E., & Bergeron, C. B. (1999). Dementia as the most common presentation of cortical-basal ganglionic degeneration. Neurology. https://doi.org/10.1212/wnl.53.9.1969

Vancouver

Grimes DA, Lang AE, Bergeron CB. Dementia as the most common presentation of cortical-basal ganglionic degeneration. Neurology. 1999. doi:10.1212/wnl.53.9.1969. PMID: 10599767.

BibTeX

@article{grimes1999-10599767,
  author  = {Grimes, D. A. and Lang, A. E. and Bergeron, C. B.},
  title   = {{Dementia as the most common presentation of cortical-basal ganglionic degeneration}},
  journal = {Neurology},
  year    = {1999},
  doi     = {10.1212/wnl.53.9.1969},
  pmid    = {10599767},
  url     = {https://doi.org/10.1212/wnl.53.9.1969}
}

Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. Check the citation against the original before you use it.

Key findings

Why it matters

This study of 13 patients with pathologically confirmed cortical-basal ganglionic degeneration found that dementia was the most common presentation. It is a small case series and does not test any treatment, cure, or prevention for Alzheimer's disease.

Study details

How this study scored 47/100
How this study's score is builtJournal tier 9 of 10; Journal's citation record 4 of 4; Study design 0 of 12; Strength of evidence 1 of 5; Peer-review validation 10 of 10; How recent 1 of 5; Sample size 1 of 4; Effect reported 0 of 3; Studied in people 3 of 3; Randomised / blinded 0 of 2; Times cited 5 of 7; Citations per year 2 of 5; Impact for its field and year 3 of 6; Cited by studies here 2 of 6; Still being cited 1 of 4; Senior author's track record 2 of 4; Institution's track record left out, no data; Multi-centre collaboration 0 of 3; Indexed in PubMed 2 of 2; Free to read 0 of 2. 46 of the 97 points it could be judged on, which is 47 of 100. Total 47 of 100.46 of the 97 points we could judge = 47 of 100

Published in a leading specialty journal. Scored zero for study design, effect reported and randomised / blinded because the record does not state it. We have no data on institution's track record, so that was left out: it earned 46 of the 97 points we could judge it on, which is 47 out of 100.

ComponentPointsWhy
Journal tier 9 / 10 Tier 2 — leading specialty journal (Neurology)
Journal's citation record 4 / 4 Neurology: journal h-index 525 (OpenAlex, 2026-10-29)
Study design 0 / 12 No study design recorded — scores zero, not guessed (not stated in the record — scored 0)
Strength of evidence 1 / 5 Rated “low” in our summary
Peer-review validation 10 / 10 Peer-reviewed. Published as an article in a named peer-reviewed journal.
How recent 1 / 5 1999 — older than 20 years, still counted
Sample size 1 / 4 13 participants
Effect reported 0 / 3 No effect size reported — scores zero (not stated in the record — scored 0)
Studied in people 3 / 3 Studied in people (participant count stated)
Randomised / blinded 0 / 2 No randomisation or blinding stated — scores zero (not stated in the record — scored 0)
Times cited 5 / 7 Cited 218 times (OpenAlex, 2026-10-10)
Citations per year 2 / 5 7.5 citations a year over 29 year(s) since 1999
Impact for its field and year 3 / 6 Cited 4.7× the average for papers of its field and year (OpenAlex FWCI)
Cited by studies here 2 / 6 Cited by 6 other studies in this library
Still being cited 1 / 4 Cited 7 times in 2024–2026 (2026 still in progress; OpenAlex)
Senior author's track record 2 / 4 Last-listed author Catherine Bergeron: h-index 35 (OpenAlex, whole career)
Institution's track record — / 3 No institution listed in OpenAlex — left out of this score
Multi-centre collaboration 0 / 3 OpenAlex lists 0 institution(s) in 0 countries — scores zero (affiliation lists can be incomplete)
Indexed in PubMed 2 / 2 Indexed in PubMed (PMID 10599767)
Free to read 0 / 2 Behind a paywall — scores zero
Points 46 / 97 Scored on 19 of 20 parts. We have no data for the rest, so they are left out: 46 of the 97 points we could judge it on is 47 out of 100.
Total 47 / 100 —

What each of these 20 components measures, and what this score is not →

Read the original

May need a subscription OpenAlex found no free copy of the full text (checked 6 Feb 1020), so the publisher may charge for it. The PubMed abstract is free.

Studies in the library that share something with this one. The line above each title says what.

Studies this one cites

Referenced by this study and also in the alzhub library, so you can read them here.

Later studies that cite this one

6 studies in the alzhub library list this one in their references.

Related studies in Disparities

Also tagged “bodies”

1,017 studies in the library carry the topic tag “bodies”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 1,017 tagged studies.

Studies sharing this one's topic tags

Similar studies

More on Disparities

See all studies in Disparities →